[
  {
    "drug_name": "semaglutide",
    "global_market_size_usd_bn": 70.4,
    "forecast_market_size_usd_bn_2030": 140.5,
    "cagr_percent": 12.7,
    "patient_population_millions": 650,
    "treated_population_percent": 14.8,
    "number_of_competitors": 12,
    "branded_vs_generic_mix": "branded-dominant",
    "key_competitor_classes": [
      "GLP-1 agonists",
      "Dual GLP-1/GIP",
      "Insulin",
      "SGLT2 inhibitors"
    ],
    "commercial_signals": [
      "Strong payer uptake in US and EU",
      "Supply constraints impacting near-term sales",
      "GLP-1s shifting standard of care",
      "Strong guideline support"
    ],
    "risks": [
      "Pricing pressure from next-generation incretins",
      "Long-term cardiovascular outcomes scrutiny",
      "Formulary exclusions in price-sensitive markets"
    ]
  },
  {
    "drug_name": "ketamine",
    "global_market_size_usd_bn": 5.0,
    "forecast_market_size_usd_bn_2030": 13.0,
    "cagr_percent": 16.2,
    "patient_population_millions": 30,
    "treated_population_percent": 4.7,
    "number_of_competitors": 5,
    "branded_vs_generic_mix": "branded-specialty",
    "key_competitor_classes": [
      "NMDA antagonists",
      "Psychedelic-assisted therapy",
      "neurosteroid antidepressants"
    ],
    "commercial_signals": [
      "Clinic-based administration models",
      "Rapid onset differentiates from SSRIs",
      "Growing recognition of postpartum depression as a distinct treatable condition",
      "Rapid-acting antidepressants gaining payer interest",
      "Specialty clinic-driven adoption"
    ],
    "risks": [
      "Abuse potential",
      "Reimbursement uncertainty",
      "Administration setting constraints (IV/clinic-based)",
      "Safety and abuse perception risks",
      "Reimbursement variability across regions"
    ]
  },
  {
    "drug_name": "metformin",
    "global_market_size_usd_bn": 6.2,
    "forecast_market_size_usd_bn_2030": 21.0,
    "cagr_percent": 22.1,
    "patient_population_millions": 115,
    "treated_population_percent": 2.5,
    "number_of_competitors": 15,
    "branded_vs_generic_mix": "generic-heavy",
    "key_competitor_classes": [
      "Metabolic modulators",
      "FXR agonists"
    ],
    "commercial_signals": [
      "High unmet need with no approved therapies",
      "Multiple late-stage pipeline assets"
    ],
    "risks": [
      "High clinical failure rates in NASH",
      "Regulatory uncertainty on endpoints"
    ]
  },
  {
    "drug_name": "naltrexone",
    "global_market_size_usd_bn": 14.8,
    "forecast_market_size_usd_bn_2030": 26.0,
    "cagr_percent": 7.3,
    "patient_population_millions": 6.5,
    "treated_population_percent": 65.0,
    "number_of_competitors": 10,
    "branded_vs_generic_mix": "biologic-dominant",
    "key_competitor_classes": [
      "Anti-TNF",
      "IL-23 inhibitors"
    ],
    "commercial_signals": [
      "Biologics dominate prescribing",
      "Interest in low-cost oral adjuncts"
    ],
    "risks": [
      "Crowded biologics market",
      "Switching barriers"
    ]
  },
  {
    "drug_name": "minoxidil",
    "global_market_size_usd_bn": 9.5,
    "forecast_market_size_usd_bn_2030": 15.2,
    "cagr_percent": 6.1,
    "patient_population_millions": 180,
    "treated_population_percent": 12.0,
    "number_of_competitors": 6,
    "branded_vs_generic_mix": "generic-dominant",
    "key_competitor_classes": [
      "Topical vasodilators",
      "Anti-androgens"
    ],
    "commercial_signals": [
      "Strong OTC demand",
      "Cosmetic dermatology driven growth"
    ],
    "risks": [
      "Low barriers to entry",
      "Limited pricing power"
    ]
  }
]
